GANX Projected Dividend Yield
Gain Therapeutics Inc ( NASDAQ : GANX )Gain Therapeutics is a biotechnology company developing small molecule therapeutics to treat diseases across, several therapeutics areas, including, central nervous system disorders, lysosomal storage disorders, metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. Co.'s primary product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease, including restoration of GCase function, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and increase of dopamine levels and improved locomotor function in animal models. 20 YEAR PERFORMANCE RESULTS |
GANX Dividend History Detail GANX Dividend News GANX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |